stockrowBridgeBio Pharma, Inc.
BBIO Healthcare Biotechnology
BridgeBio Pharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $502.1 million, up 126.3% from fiscal 2024.
- Revenue
- +192.6%
- EPS
- +55.8%
- Free cash flow
- +60.5%
- Total debt
- +4.21%
Quarter to September 2026, against a year earlier
Follow BBIO
Alert me
BridgeBio Pharma, Inc. (BBIO) Operating cash flow
BridgeBio Pharma, Inc.'s operating cash flow for fiscal 2025 was −$445.9M, compared with −$520.7M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$369.0M. Over the past ten years it has ranged from −$527.7M (fiscal 2023) to −$40.5M (fiscal 2017); the current reading is higher than 44% of that period. BridgeBio Pharma, Inc. ranks 582nd of 603 Biotechnology companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | −$445.9M | — |
| FY2024 | −$520.7M | — |
| FY2023 | −$527.7M | — |
| FY2022 | −$419.5M | — |
| FY2021 | −$497.9M | — |
| FY2020 | −$399.7M | — |
| FY2019 | −$253.6M | — |
| FY2018 | −$136.6M | — |
| FY2017 | −$40.5M | — |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Sep 2026 | −$44.2M | — |
| Jun 2026 | −$71.1M | — |
| Mar 2026 | −$197.3M | — |
| Dec 2025 | −$56.4M | — |
| 30 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| JAZZ Jazz Pharmaceuticals PLC compare | $1.7B |
| EXEL Exelixis, Inc. compare | $1.2B |
| HALO Halozyme Therapeutics, Inc. compare | $898.3M |
| BMRN BioMarin Pharmaceutical Inc. compare | $676.6M |
| ASND Ascendis Pharma A/S compare | $404.1M |
| TECH Bio-Techne Corp compare | $292.1M |
| KYMR Kymera Therapeutics, Inc. compare | −$287.6M |
| BBIO BridgeBio Pharma, Inc. | −$369.0M |
| SMMT Summit Therapeutics PLC compare | −$458.4M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on BBIO
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement